Commentary

Video

Highlights in MPNs, CLL With Drs Prithviraj Bose and Javier Pinilla Ibarz

Author(s):

Prithviraj Bose, MD,Javier Pinilla, MD, PhD

Prithviraj Bose, MD, of The University of Texas MD Anderson Cancer Center, and Javier Pinilla Ibarz, MD, PhD, of Moffitt Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest in myeloproliferative neoplasms and chronic lymphocytic leukemia, respectively, from the 2024 ASH Annual Meeting.

Prithviraj Bose, MD, of The University of Texas MD Anderson Cancer Center, and Javier Pinilla Ibarz, MD, PhD, of Moffitt Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest in myeloproliferative neoplasms and chronic lymphocytic leukemia, respectively, from the 2024 ASH Annual Meeting.

Related Videos
Farrukh Awan, MD
Paolo Ghia, MD, PhD, full professor, medical oncology, Università Vita-Salute San Raffaele; head, Laboratory of B-Cell Neoplasia, director, Strategic Research Program on CLL, ORCCS Ospedale San Raffaele
Craig Eckfeldt, MD
Sangeetha Venugopal, MD, MS, discusses factors that inform JAK inhibitor selection in myelofibrosis.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Related Content
Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
January 15th 2025

Neoadjuvant SHR-A1811 Produces pCRs in Early HER2+ Breast Cancer

Onyee Chan, MD, hematologist/oncologist, Moffitt Cancer Center Magnolia Campus; Bradley D. Hunter, MD, medical director, Oncology, director, Immune Effector Cell Therapy, Intermountain Healthcare
December 24th 2024

Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD

HNSCC | Image Credit: ©shahzaib – stock.adobe.com
January 14th 2025

Adjuvant Nivolumab Plus Chemoradiotherapy Meets DFS End Point in Locally Advanced HNSCC

Jaffer A. Ajani, MD, GI medical oncologist, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
November 14th 2024

FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma

Chronic Lymphocytic Leukemia | stock.adobe.com
January 13th 2025

Zanubrutinib Plus Obinutuzumab/Venetoclax Associated With Durable uMRD4 Outcomes in Treatment-Naive CLL

Naseema Gangat, MBBS, of Mayo Clinic
January 10th 2025

Novel Agents May Enhance JAK Inhibitor Efficacy and Augment the Myelofibrosis Treatment Paradigm